Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -10773.46% is 245% below its 5-year average of -3121.24%, near the low end of its 5-year range (-286417.65%–1858011.00%).
2343.90% below its 12-month average of -440.83%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-10773.46%
NET PROFIT MARGIN AVG TTM
-440.83%
NET PROFIT MARGIN AVG 3Y
-881.41%
NET PROFIT MARGIN AVG 5Y
-3121.24%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2343.90%
CURRENT VS 3Y AVG
-1122.30%
CURRENT VS 5Y AVG
-245.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.06%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
-17955666.67%
vs the sector median at left
Inhibrx Biosciences Inc.
Market Cap
$1.39B
Net Profit Margin
-10773.46%
TTM Avg
-440.83%
3Y Avg
-881.41%
5Y Avg
-3121.24%
Market Cap
$1.40B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.41B
Net Profit Margin
82.37%
TTM Avg
-82.37%
3Y Avg
-592.43%
5Y Avg
-414.63%
Market Cap
$1.41B
Net Profit Margin
2.93%
TTM Avg
3.18%
3Y Avg
2.55%
5Y Avg
2.48%
Market Cap
$1.43B
Net Profit Margin
-81.79%
TTM Avg
-93.52%
3Y Avg
-130.36%
5Y Avg
-119.92%
Market Cap
$1.43B
Net Profit Margin
-667.95%
TTM Avg
15.59%
3Y Avg
7.79%
5Y Avg
7.79%
Market Cap
$1.34B
Net Profit Margin
324.88%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.44B
Net Profit Margin
-16.75%
TTM Avg
-1.75%
3Y Avg
-3.69%
5Y Avg
-6.61%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.39B | -10773.46% | -440.83% | -881.41% | -3121.24% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 82.37% | -82.37% | -592.43% | -414.63% |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 2.93% | 3.18% | 2.55% | 2.48% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -81.79% | -93.52% | -130.36% | -119.92% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | -667.95% | 15.59% | 7.79% | 7.79% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | 324.88% | 0.00% | 0.00% | 0.00% |
| Certara, Inc. (CERT)vs › | $1.44B | -16.75% | -1.75% | -3.69% | -6.61% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.34B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-10386.5%
Net Profit Margin
-10773.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -2204.15% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -47865.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 1858011.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -5728.52% |
| 2023-09-30 | -43520.17% |
| 2023-06-30 | -156840.00% |
| 2023-03-31 | -286417.65% |
| 2022-12-31 | -14932.48% |
| 2022-09-30 | -14621.22% |
| 2022-06-30 | -5306.89% |
| 2022-03-31 | -3415.74% |
| 2021-12-31 | -747.14% |
| 2021-09-30 | -812.80% |
| 2021-06-30 | -2170.86% |
| 2021-03-31 | -2235.11% |
| 2020-12-31 | -635.77% |
| 2020-09-30 | -351.82% |
| 2020-06-30 | -536.44% |
| 2020-03-31 | -2304.24% |
| 2019-12-31 | -6106.74% |
| 2019-09-30 | -2539.42% |
| 2019-06-30 | -1108.50% |
| 2019-03-31 | -54.71% |
| 2018-12-31 | -194.40% |
| 2018-06-30 | -286.24% |
| 2018-03-31 | -374.20% |
| 2017-12-31 | -2811.03% |
